sarpogrelate has been researched along with Cardiac Hypertrophy in 1 studies
sarpogrelate: structure given in first source
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sarpogrelate was developed as an antiplatelet agent antagonizing 5-hydroxytryptamine (5-HT) receptors." | 1.31 | The effects of sarpogrelate on cardiomyocyte hypertrophy. ( Harada, M; Hosoya, T; Ikeda, K; Nakao, K; Tojo, K; Tokudome, G, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeda, K | 1 |
| Tojo, K | 1 |
| Tokudome, G | 1 |
| Hosoya, T | 1 |
| Harada, M | 1 |
| Nakao, K | 1 |
1 other study available for sarpogrelate and Cardiac Hypertrophy
| Article | Year |
|---|---|
The effects of sarpogrelate on cardiomyocyte hypertrophy.
Topics: Angiotensin II; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Endothelin-1; Fibroblasts; | 2000 |